Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Cellular localization and function of Fas ligand (CD95L) in tumors.

Kurooka M, Nuovo GJ, Caligiuri MA, Nabel GJ.

Cancer Res. 2002 Mar 1;62(5):1261-5.

2.

CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.

Nishimatsu H, Takeuchi T, Ueki T, Kajiwara T, Moriyama N, Ishida T, Li B, Kakizoe T, Kitamura T.

Cancer Immunol Immunother. 1999 Apr;48(1):56-61.

PMID:
10235489
3.

Inhibition of the alloantibody response by CD95 ligand.

Arai H, Chan SY, Bishop DK, Nabel GJ.

Nat Med. 1997 Aug;3(8):843-8.

PMID:
9256273
4.
5.

The influence of CD95L expression on tumor rejection in mice.

Igney FH, Behrens CK, Krammer PH.

Eur J Immunol. 2003 Oct;33(10):2811-21.

6.
7.

Tumor counterattack: fact or fiction?

Igney FH, Krammer PH.

Cancer Immunol Immunother. 2005 Nov;54(11):1127-36. Epub 2005 May 12. Review.

PMID:
15889255
8.

CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies.

Sträter J, Walczak H, Hasel C, Melzner I, Leithäuser F, Möller P.

Cell Death Differ. 2001 Mar;8(3):273-8.

10.
11.

Regulation of the proinflammatory effects of Fas ligand (CD95L).

Chen JJ, Sun Y, Nabel GJ.

Science. 1998 Nov 27;282(5394):1714-7.

12.

Tumor expression of Fas ligand (CD95L) and the consequences.

Walker PR, Saas P, Dietrich PY.

Curr Opin Immunol. 1998 Oct;10(5):564-72. Review.

PMID:
9794830
13.

Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.

Yoshimoto Y, Kawada M, Ikeda D, Ishizuka M.

Int Immunopharmacol. 2005 Feb;5(2):281-8.

PMID:
15652759
14.
15.

CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells.

Reinehr R, Sommerfeld A, Häussinger D.

Gastroenterology. 2008 May;134(5):1494-506. doi: 10.1053/j.gastro.2008.02.021. Epub 2008 Feb 14.

PMID:
18471522
16.

The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.

Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J.

J Am Coll Cardiol. 2005 Apr 5;45(7):1018-24.

17.

Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.

Nonaka K, Saio M, Suwa T, Frey AB, Umemura N, Imai H, Ouyang GF, Osada S, Balazs M, Adany R, Kawaguchi Y, Yoshida K, Takami T.

J Leukoc Biol. 2008 Sep;84(3):679-88. doi: 10.1189/jlb.1107729. Epub 2008 Jun 19.

18.

Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor.

Shimizu M, Yoshimoto T, Sato M, Morimoto J, Matsuzawa A, Takeda Y.

Int J Cancer. 2005 May 10;114(6):926-35.

19.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk